The findings of a study published last week by the journal Neuropsychopharmacology “provide proof of principle supporting potential of CBD [cannabidiol] in relapse prevention”.
“Cannabidiol (CBD), the major non-psychoactive constituent of Cannabis sativa, has received attention for therapeutic potential in treating neurologic and psychiatric disorders”, states the study’s abstract. “Recently, CBD has also been explored for potential in treating drug addiction.” The study notes that substance use disorders “are chronically relapsing conditions and relapse risk persists for multiple reasons including craving induced by drug contexts, susceptibility to stress, elevated anxiety, and impaired impulse control.” Here, researchers “evaluated the “anti-relapse” potential of a transdermal CBD preparation in animal models of drug seeking, anxiety and impulsivity.”
For the study, rats with alcohol or cocaine self-administration histories “received transdermal CBD at 24 h intervals for 7 days and were tested for context and stress-induced reinstatement, as well as experimental anxiety on the elevated plus maze.” Effects on impulsive behavior were established using “a delay-discounting task following recovery from a 7-day dependence-inducing alcohol intoxication regimen.”
Researchers found that; “CBD attenuated context-induced and stress-induced drug seeking without tolerance, sedative effects, or interference with normal motivated behavior. Following treatment termination, reinstatement remained attenuated up to ≈5 months although plasma and brain CBD levels remained detectable only for 3 days.” CBD also “reduced experimental anxiety and prevented the development of high impulsivity in rats with an alcohol dependence history.”
The study concludes by stating that; “The results provide proof of principle supporting potential of CBD in relapse prevention along two dimensions CBD: beneficial actions across several vulnerability states, and long-lasting effects with only brief treatment. The findings also inform the ongoing medical marijuana debate concerning medical benefits of non-psychoactive cannabinoids and their promise for development and use as therapeutics.”
The study can be found by clicking here (though we note that the full study is behind a paywall).